ClinicalTrials.gg
CompletedNCT04487067AMETHISTAUpdated Sep 22, 2025Results posted

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

A Phase 3 interventional study of Atezolizumab and Bevacizumab in Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche. Completed at 21 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Enrollment
12th of 41
152 · median 40
Started
2020
with 3 others
Phase 3
11 of 41
2 open now
Registered
7th of 41
by date
Lead sponsor
6 of 41
Hoffmann-La Roche

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 12th largest by enrollment, is one of 4 that started in 2020, is one of 11 in phase 3, and was the 7th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unresectable HCC with diagnosis confirmed by histology, with a within 6 months from recruitment;
  • Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies;
  • No prior systemic therapy for HCC;
  • At least one measurable untreated lesion;
  • Patients who received prior local therapy are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with version 1.1;
  • Performance Status of 0 or 1 within 7 days prior to recruitment;
  • class A within 7 days prior to recruitment;
  • Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed. In case of varices at high risk of bleeding (corresponding to medium (F2) or large (F3) varices, or F1 varices with cherry red spots or red wale marking) prophylatic treatment per local standard of care must be adopted prior to enrollment. Patients who have undergone an EGD within 6 months of prior to initiation of study treatment do not need to repeat the procedure provided they had no varices at high risk of bleeding;
  • Adequate hematologic and end-organ function
  • Resolution of any acute, treatment-related toxicity from prior therapy to Grade \<= 1 prior to study entry, with the exception of alopecia
  • Negative test at screening with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a ≥200µL, and have an undetectable viral load;
  • In patients with viral HCC, documented virology status of hepatitis, as confirmed by screening and serology test;
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, and agreement to refrain from donating eggs.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • History of or ;
  • Active or history of disease or immune deficiency;
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan;
  • Known active tuberculosis;
  • Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina;
  • History of other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of or death;
  • Prior allogeneic stem cell or solid organ transplantation;
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab;
  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC;
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding;
  • A prior bleeding event due to oesophageal and/or gastric varices within 6 months prior to initiation of study treatment;
  • Clinically evident ascites;
  • Co-infection of and ;
  • Co-infection with HBV and hepatitis D viral infection;
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures;
  • uncontrolled or symptomatic hypercalcemia;
  • Inadequately controlled arterial hypertension;
  • Significant vascular disease within 6 months prior to initiation of study treatment;
  • History of haemoptysis;
  • Evidence of bleeding diathesis or significant coagulopathy;
  • History of gastrointestinal (GI) fistula, GI perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment;
  • History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding prior to initiation of study treatment;
  • Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses of large volume;
  • Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Atezolizumab + Bevacizumab

    Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)

    Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • Atezolizumab 1200 mg IV infusion q3w

    Also known as: Tecentriq

  • Bevacizumab 15 mg/kg IV Q3W

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AEs was graded using NCI CTCAE v5.0. Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4=Life-threatening consequences, urgent intervention indicated; Grade 5=Death related to AE.

    Time frame: Up to approximately 47.6 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from initiation of study treatment to death from any cause. Kaplan-Meier (K-M) method was used to estimate the OS.

    Time frame: Up to approximately 47.6 months

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as AEs with onset date on or after the start of the first study treatment component. Number of participants with any TEAEs are reported here.

    Time frame: Up to approximately 47.6 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from initiation of study treatment to the first occurrence of disease progression (PD) or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm). Participants alive and without any PD were censored at the last assessment date. K-M method was used to estimate the PFS.

    Time frame: Up to approximately 47.6 months

  4. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with complete or partial response (CR or PR), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.

    Time frame: Up to approximately 47.6 months

  5. Time to Progression (TTP)

    TTP was defined as the time from initiation of study treatment to the first occurrence of PD, as determined by the investigator according to RECIST v1.1. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants without any PD were censored at the last assessment date. K-M method was used to estimate the TTP.

    Time frame: Up to approximately 47.6 months

  6. Duration of Response (DOR)

    DOR was defined as the time from the first occurrence of a documented objective response (CR or PR) to PD or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants who were alive and without any PD were censored at the last assessment date. K-M method was used to estimate the DOR.

    Time frame: Up to approximately 47.6 months

  7. Post-progression Survival (PPS)

    PPS was defined as the time from the first occurrence of PD as determined by the investigator according to RECIST v1.1 to death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants who were alive were censored at the last assessment date. K-M method was used to estimate the PPS.

    Time frame: Up to approximately 47.6 months

  8. Number of Participants Reporting Severe Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire

    Participants self-reported symptomatic AEs using PRO-CTCAE, a validated item bank used to characterize presence, frequency of occurrence, severity, \&/or degree of interference with daily function of 78 patient-reportable symptomatic treatment toxicities. PRO-CTCAE contains questions that are rated either dichotomously (for determination of presence vs. absence) or on a 5-point Likert scale (for determination of frequency of occurrence,severity,\& interference with daily function). Treatment toxicities can occur with observable signs (e.g.,vomiting)/ non-observable symptoms (e.g.,nausea). A subset of 14 symptoms most applicable to current treatments were selected for this study. Symptoms were selected based on toxicities associated with the drug's class, mechanism of action, or mode of administration, and toxicities reported with the drug in another indication. Number of participants who reported severe symptoms per the PRO-CTCAE questionnaire on Day 1 of each cycle is reported here.

    Time frame: From Cycle 1 Day 1 to Cycle 63 Day 1 (1 Cycle = 21 days)

  9. Number of Participants Reporting Very Severe Symptoms in PRO-CTCAE Questionnaire

    Participants self-reported symptomatic AEs using PRO-CTCAE, a validated item bank used to characterize presence, frequency of occurrence, severity, \&/or degree of interference with daily function of 78 patient-reportable symptomatic treatment toxicities. PRO-CTCAE contains questions that are rated either dichotomously (for determination of presence vs. absence) or on a 5-point Likert scale (for determination of frequency of occurrence,severity,\& interference with daily function). Treatment toxicities can occur with observable signs (e.g.,vomiting)/ non-observable symptoms (e.g.,nausea). A subset of 14 symptoms most applicable to current treatments were selected for this study. Symptoms were selected based on toxicities associated with the drug's class, mechanism of action, or mode of administration, \&toxicities reported with the drug in another indication. Number of participants who reported very severe symptoms per the PRO-CTCAE questionnaire on Day 1 of each cycle is reported here.

    Time frame: From Cycle 1 Day 1 to Cycle 63 Day 1 (1 Cycle = 21 days)

Other outcomes

  1. Number of Participants Starting Second or Further Lines of Treatment

    Time frame: Up to approximately 47.6 months

07

Results

Posted Sep 22, 2025

Participant flow

A total of 152 participants with unresectable hepatocellular carcinoma (HCC) and no prior systemic treatment took part in the study at 21 investigative sites in Italy from 25 August 2020 to 13 August 2024.

Participant flow — Overall Study
MilestoneAtezolizumab + Bevacizumab
Started152
Safety analysis population149
Completed21
Not completed131
Withdrew: Adverse event3
Withdrew: Death other than progressive disease60
Withdrew: Death due to progressive disease40
Withdrew: Lost to follow-up3
Withdrew: Progressive disease1
Withdrew: Protocol violation3
Withdrew: Participant discontinued from study as per protocol6
Withdrew: Withdrawal by subject15

Outcome measures

PrimaryNumber of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AEs was graded using NCI CTCAE v5.0. Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4=Life-threatening consequences, urgent intervention indicated; Grade 5=Death related to AE.

Time frame:
Up to approximately 47.6 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage
ParticipantsAtezolizumab + Bevacizumab
Grade 317
Grade 43
Grade 52
SecondaryOverall Survival (OS)

OS was defined as the time from initiation of study treatment to death from any cause. Kaplan-Meier (K-M) method was used to estimate the OS.

Time frame:
Up to approximately 47.6 months
Reported as:
Median · months
Overall Survival (OS)
monthsAtezolizumab + Bevacizumab
Overall Survival (OS)20.76 (16.85 to 26.35)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as AEs with onset date on or after the start of the first study treatment component. Number of participants with any TEAEs are reported here.

Time frame:
Up to approximately 47.6 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAtezolizumab + Bevacizumab
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)144
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from initiation of study treatment to the first occurrence of disease progression (PD) or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm). Participants alive and without any PD were censored at the last assessment date. K-M method was used to estimate the PFS.

Time frame:
Up to approximately 47.6 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsAtezolizumab + Bevacizumab
Progression-free Survival (PFS)8.80 (7.89 to 11.24)
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with complete or partial response (CR or PR), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.

Time frame:
Up to approximately 47.6 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsAtezolizumab + Bevacizumab
Objective Response Rate (ORR)28.29 (0.2173 to 0.3592)
SecondaryTime to Progression (TTP)

TTP was defined as the time from initiation of study treatment to the first occurrence of PD, as determined by the investigator according to RECIST v1.1. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants without any PD were censored at the last assessment date. K-M method was used to estimate the TTP.

Time frame:
Up to approximately 47.6 months
Reported as:
Median · months
Time to Progression (TTP)
monthsAtezolizumab + Bevacizumab
Time to Progression (TTP)11.24 (8.48 to 15.77)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first occurrence of a documented objective response (CR or PR) to PD or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants who were alive and without any PD were censored at the last assessment date. K-M method was used to estimate the DOR.

Time frame:
Up to approximately 47.6 months
Reported as:
Median · months
Duration of Response (DOR)
monthsAtezolizumab + Bevacizumab
Duration of Response (DOR)17.35 (13.54 to 27.24)
SecondaryPost-progression Survival (PPS)

PPS was defined as the time from the first occurrence of PD as determined by the investigator according to RECIST v1.1 to death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants who were alive were censored at the last assessment date. K-M method was used to estimate the PPS.

Time frame:
Up to approximately 47.6 months
Reported as:
Median · months
Post-progression Survival (PPS)
monthsAtezolizumab + Bevacizumab
Post-progression Survival (PPS)11.27 (8.41 to 13.80)
SecondaryNumber of Participants Reporting Severe Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire

Participants self-reported symptomatic AEs using PRO-CTCAE, a validated item bank used to characterize presence, frequency of occurrence, severity, \&/or degree of interference with daily function of 78 patient-reportable symptomatic treatment toxicities. PRO-CTCAE contains questions that are rated either dichotomously (for determination of presence vs. absence) or on a 5-point Likert scale (for determination of frequency of occurrence,severity,\& interference with daily function). Treatment toxicities can occur with observable signs (e.g.,vomiting)/ non-observable symptoms (e.g.,nausea). A subset of 14 symptoms most applicable to current treatments were selected for this study. Symptoms were selected based on toxicities associated with the drug's class, mechanism of action, or mode of administration, and toxicities reported with the drug in another indication. Number of participants who reported severe symptoms per the PRO-CTCAE questionnaire on Day 1 of each cycle is reported here.

Time frame:
From Cycle 1 Day 1 to Cycle 63 Day 1 (1 Cycle = 21 days)
Reported as:
Count of participants · Participants
Number of Participants Reporting Severe Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire
ParticipantsAtezolizumab + Bevacizumab
Cycle 1 Day 139
Cycle 2 Day 133
Cycle 3 Day 123
Cycle 4 Day 130
Cycle 5 Day 123
Cycle 6 Day 122
Cycle 7 Day 117
Cycle 8 Day 114
Cycle 9 Day 119
Cycle 10 Day 116
Cycle 11 Day 117
Cycle 12 Day 116
Cycle 13 Day 113
Cycle 14 Day 113
Cycle 15 Day 19
Cycle 16 Day 18
Cycle 17 Day 110
Cycle 18 Day 110
Cycle 19 Day 18
Cycle 20 Day 111
Cycle 21 Day 15
Cycle 22 Day 16
Cycle 23 Day 18
Cycle 24 Day 110
Cycle 25 Day 18
Cycle 26 Day 17
Cycle 27 Day 18
Cycle 28 Day 110
Cycle 29 Day 16
Cycle 30 Day 17
Cycle 31 Day 17
Cycle 32 Day 16
Cycle 33 Day 16
Cycle 34 Day 17
Cycle 35 Day 19
Cycle 36 Day 18
Cycle 37 Day 17
Cycle 38 Day 19
Cycle 39 Day 18
Cycle 40 Day 18
Cycle 41 Day 15
Cycle 42 Day 16
Cycle 43 Day 13
Cycle 44 Day 13
Cycle 45 Day 13
Cycle 46 Day 12
Cycle 47 Day 12
Cycle 48 Day 13
Cycle 49 Day 13
Cycle 50 Day 12
Cycle 51 Day 13
Cycle 52 Day 12
Cycle 53 Day 12
Cycle 54 Day 11
Cycle 55 Day 11
Cycle 56 Day 11
Cycle 57 Day 10
Cycle 58 Day 10
Cycle 59 Day 10
Cycle 60 Day 10
Cycle 61 Day 10
Cycle 62 Day 10
Cycle 63 Day 10
SecondaryNumber of Participants Reporting Very Severe Symptoms in PRO-CTCAE Questionnaire

Participants self-reported symptomatic AEs using PRO-CTCAE, a validated item bank used to characterize presence, frequency of occurrence, severity, \&/or degree of interference with daily function of 78 patient-reportable symptomatic treatment toxicities. PRO-CTCAE contains questions that are rated either dichotomously (for determination of presence vs. absence) or on a 5-point Likert scale (for determination of frequency of occurrence,severity,\& interference with daily function). Treatment toxicities can occur with observable signs (e.g.,vomiting)/ non-observable symptoms (e.g.,nausea). A subset of 14 symptoms most applicable to current treatments were selected for this study. Symptoms were selected based on toxicities associated with the drug's class, mechanism of action, or mode of administration, \&toxicities reported with the drug in another indication. Number of participants who reported very severe symptoms per the PRO-CTCAE questionnaire on Day 1 of each cycle is reported here.

Time frame:
From Cycle 1 Day 1 to Cycle 63 Day 1 (1 Cycle = 21 days)
Reported as:
Count of participants · Participants
Number of Participants Reporting Very Severe Symptoms in PRO-CTCAE Questionnaire
ParticipantsAtezolizumab + Bevacizumab
Cycle 1 Day 115
Cycle 2 Day 118
Cycle 3 Day 112
Cycle 4 Day 112
Cycle 5 Day 110
Cycle 6 Day 111
Cycle 7 Day 17
Cycle 8 Day 111
Cycle 9 Day 17
Cycle 10 Day 17
Cycle 11 Day 16
Cycle 12 Day 15
Cycle 13 Day 17
Cycle 14 Day 17
Cycle 15 Day 17
Cycle 16 Day 18
Cycle 17 Day 14
Cycle 18 Day 15
Cycle 19 Day 14
Cycle 20 Day 14
Cycle 21 Day 11
Cycle 22 Day 14
Cycle 23 Day 12
Cycle 24 Day 13
Cycle 25 Day 14
Cycle 26 Day 14
Cycle 27 Day 13
Cycle 28 Day 13
Cycle 29 Day 13
Cycle 30 Day 12
Cycle 31 Day 14
Cycle 32 Day 13
Cycle 33 Day 13
Cycle 34 Day 15
Cycle 35 Day 15
Cycle 36 Day 13
Cycle 37 Day 16
Cycle 38 Day 14
Cycle 39 Day 14
Cycle 40 Day 14
Cycle 41 Day 14
Cycle 42 Day 15
Cycle 43 Day 14
Cycle 44 Day 14
Cycle 45 Day 12
Cycle 46 Day 12
Cycle 47 Day 11
Cycle 48 Day 11
Cycle 49 Day 10
Cycle 50 Day 11
Cycle 51 Day 10
Cycle 52 Day 11
Cycle 53 Day 11
Cycle 54 Day 10
Cycle 55 Day 11
Cycle 56 Day 10
Cycle 57 Day 11
Cycle 58 Day 10
Cycle 59 Day 10
Cycle 60 Day 10
Cycle 61 Day 10
Cycle 62 Day 10
Cycle 63 Day 10
Other pre-specifiedNumber of Participants Starting Second or Further Lines of Treatment
Time frame:
Up to approximately 47.6 months

No measurements were reported for this outcome.

Adverse events

Collected over Other AEs: From initiation of study drug until 30 days after the final dose or initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 47.6 months) SAEs, and All-cause mortality: From initiation of study drug until 90 days after the final dose or initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 47.6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atezolizumab + Bevacizumab102/149 (68.5%)62/149 (41.6%)142/149 (95.3%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventAtezolizumab + Bevacizumab
SepsisInfections and infestations5/149
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/149
Oesophageal varices haemorrhageGastrointestinal disorders4/149
COVID-19Infections and infestations4/149
AnaemiaBlood and lymphatic system disorders3/149
AscitesGastrointestinal disorders3/149
Gastrointestinal haemorrhageGastrointestinal disorders3/149
MelaenaGastrointestinal disorders2/149
Upper gastrointestinal haemorrhageGastrointestinal disorders2/149
Oedema peripheralGeneral disorders2/149
Most frequent other events
Showing 10 of 34
Most frequent other events
EventAtezolizumab + Bevacizumab
AstheniaGeneral disorders64/149
HypertensionVascular disorders51/149
DiarrhoeaGastrointestinal disorders42/149
PruritusSkin and subcutaneous tissue disorders36/149
Decreased AppetiteMetabolism and nutrition disorders33/149
PyrexiaGeneral disorders32/149
ProteinuriaRenal and urinary disorders28/149
FatigueGeneral disorders26/149
Abdominal painGastrointestinal disorders25/149
ArthralgiaMusculoskeletal and connective tissue disorders24/149

Baseline characteristics

Intent-to-treat (ITT) population included all participants who signed the informed consent form (ICF) and were enrolled in the study.

Age, Continuous
Age, Continuous(years)Atezolizumab + Bevacizumab
Mean67.1 ± 10.52
Sex: Female, Male
Sex: Female, Male(Participants)Atezolizumab + Bevacizumab
Female31
Male121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atezolizumab + Bevacizumab
Hispanic or Latino5
Not Hispanic or Latino141
Unknown or Not Reported6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atezolizumab + Bevacizumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White145
More than one race0
Unknown or Not Reported4
08

Study locations

21 sites
  • IRCCS Ospedale Casa Sollievo Della Sofferenza
    San Giovanni Rotondo, Apulia 71013, Italy
  • Fondazione Pascale
    Naples, Campania 80100, Italy
  • Azienda Osp Uni Seconda Università Degli Studi Di Napoli
    Naples, Campania 80131, Italy
  • Ospedale del Mare
    Naples, Campania 80147, Italy
  • A.O. S. Orsola Malpighi
    Bologna, Emilia-Romagna 40138, Italy
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Rome, Lazio 00151, Italy
  • Policlinico Universitario Agostino Gemelli
    Rome, Lazio 00168, Italy
  • A.O. Universitaria S. Martino Di Genova
    Genoa, Liguria 16132, Italy
  • Ospedali Riuniti - Bergamo
    Bergamo, Lombardy 24128, Italy
  • Fondazione IRCCS Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
  • Istituto Nazionale Dei Tumori
    Milan, Lombardy 20133, Italy
  • Istituto Clinico Humanitas
    Rozzano, Lombardy 20089, Italy
  • Azienda Ospedaliera Ordine Mauriziano di Torino
    Turin, Piedmont 10128, Italy
  • A.O.U. Cagliari-P.O. Monserrato
    Cagliari, Sardinia 09100, Italy
  • A.O.U. Policlinico Paolo Giaccone
    Palermo, Sicily 90127, Italy
  • Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi
    Palermo, Sicily 90127, Italy
  • A.O.U Careggi
    Florence, Tuscany 50124, Italy
  • Azlenda Ospendaliero-Universitaria Pisana
    Pisa, Tuscany 56100, Italy
  • Clinica Oncologica-Ospedali Riuniti Ancona
    Torrette, Tuscany 60020, Italy
  • IOV - Istituto Oncologico Veneto - IRCCS
    Padova, Veneto 35128, Italy
09

References and documents

Publications

  • Piscaglia F, Masi G, Martinelli E, Cabibbo G, Di Maio M, Gasbarrini A, Iavarone M, Antonuzzo L, Mazzaferro V, Ballestrero A, Garufi C, Bergamo F, Celsa C, Marino D, Tovoli F, Ponziani FR, Pressiani T, Astolfi C, Gazzoli GC, Ciardiello F, Daniele B, Rimassa L. Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial. ESMO Open. 2025 Feb;10(2):104110. doi: 10.1016/j.esmoop.2024.104110. Epub 2025 Jan 27. PubMed 39874903 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Aug 2024, 47 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 47 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2020
First posted
Jul 27, 2020
StartActual
Aug 25, 2020
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 13, 2024
Results first posted
Sep 22, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04487067
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Aug 25, 2020
Primary completion
Aug 13, 2024
Completion
Aug 13, 2024
Results posted
Sep 22, 2025
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion